Home › Kanser sa Prostate › California › Orange
Pag-aaral pangklinika para sa Kanser sa Prostate sa Orange, CA
14 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Orange (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Nagre-recruitPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Nagre-recruitPhase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Nagre-recruitPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Nagre-recruitPhase 3
- Univ Cali Irvine ALS Neuromuscular, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Nagre-recruitPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Nagre-recruitPhase 3
- UC Irvine Health, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Nagre-recruitPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Nagre-recruitPhase 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Nagre-recruitPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Nagre-recruitPhase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Nagre-recruitPhase 1/2
- UC Irvine Medical Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Nagre-recruitPhase 4
- St. Joseph Hospital, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Orange
Pag-aaral para sa Kanser sa Prostate sa ibang lungsod
- New York City, NY103 pag-aaral
- Houston, TX76 pag-aaral
- Los Angeles, CA61 pag-aaral
- Boston, MA59 pag-aaral
- St. Louis, MO46 pag-aaral
- Chicago, IL45 pag-aaral
- San Francisco, CA45 pag-aaral
- Philadelphia, PA44 pag-aaral
- Baltimore, MD43 pag-aaral
- Nashville, TN43 pag-aaral
- Seattle, WA42 pag-aaral
- Washington, DC38 pag-aaral
Iba pang pag-aaral sa Orange
- Non-Small Cell Lung Cancer25 pag-aaral
- Metastatic Cancer20 pag-aaral
- Colorectal Cancer16 pag-aaral
- Kanser sa Ovary16 pag-aaral
- Kanser sa Pancreas15 pag-aaral
- Melanoma14 pag-aaral
- Kanser sa Atay (Hepatocellular Carcinoma)14 pag-aaral
- Kanser sa Suso14 pag-aaral
- Kanser sa Baga14 pag-aaral
- Kanser sa Tiyan13 pag-aaral
- Kanser (lahat ng uri)13 pag-aaral
- Acute Myeloid Leukemia13 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.